Why Intellipharmaceutics (IPCI) Stock Is Down Today

NEW YORK (TheStreet) -- Intellipharmaceutics  (IPCI) plunged Wednesday after Maxim Group downgraded the stock to "hold" from "buy" and decreased its price target to $3 from $7.

The firm cited the company's lower-than-expected revenue and greater-than-expected expenses. Maxim also has concerns that Intellipharmaceutics' Abuse Deterrent Technology is no longer different from Teva Pharmaceuticals' (TEVA).

The stock was down 13.91% to $2.91 at 3:38 p.m. More than 1.1 million shares changed hands, compared to the average volume of 186,229.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

IPCI Chart

IPCI data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists